{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T13:27:21Z","timestamp":1777901241270,"version":"3.51.4"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100015401","name":"Shaanxi Province Key Research and Development Projects","doi-asserted-by":"publisher","award":["2020SF-172"],"award-info":[{"award-number":["2020SF-172"]}],"id":[{"id":"10.13039\/501100015401","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015401","name":"Shaanxi Province Key Research and Development Projects","doi-asserted-by":"publisher","award":["2019SF-060"],"award-info":[{"award-number":["2019SF-060"]}],"id":[{"id":"10.13039\/501100015401","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Research in Translational Medicine"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.retram.2026.103572","type":"journal-article","created":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T23:40:59Z","timestamp":1771717259000},"page":"103572","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of Venetoclax combined with Azacitidine in the treatment of relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation - a single-center retrospective study"],"prefix":"10.1016","volume":"74","author":[{"given":"Ruijun","family":"Dong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bide","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuandong","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aili","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ju","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.retram.2026.103572_bib0001","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1182\/bloodadvances.2019000388","article-title":"Allogeneic stem cell transplantation for high-risk acute leukemia and maintenance therapy: no time to waste","volume":"4","author":"Scott","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.retram.2026.103572_bib0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12185-023-03614-x","article-title":"Post-transplant maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation harmonizing multiple therapeutic modalities including targeted therapy, immunotherapy and cellular therapy","volume":"118","author":"Al-Shaibani","year":"2023","journal-title":"Int J Hematol"},{"key":"10.1016\/j.retram.2026.103572_bib0003","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3324\/haematol.2017.168716","volume":"103","author":"Schmid","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.retram.2026.103572_bib0004","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.bbmt.2014.11.007","article-title":"Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study","volume":"21","author":"Bejanyan","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.retram.2026.103572_bib0005","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.bbmt.2014.11.007","article-title":"Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study","volume":"21","author":"Bejanyan","year":"2015","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.retram.2026.103572_bib0006","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.bbmt.2010.08.001","article-title":"NCI First International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the Committee on treatment of relapse after allogeneic hematopoietic stem cell transplantation","volume":"16","author":"Porter","year":"2010","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.retram.2026.103572_bib0007","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.retram.2026.103572_bib0008","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1182\/blood-2011-08-375840","article-title":"Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation","volume":"119","author":"Schmid","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.retram.2026.103572_bib0009","article-title":"Design, synthesis, and evaluation of BCL-2 targeting PROTACs","author":"Bricelj","year":"2024","journal-title":"Chem (Easton)"},{"key":"10.1016\/j.retram.2026.103572_bib0010","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1345492","article-title":"Azacitidine induced lung injury: report and contemporary discussion on diagnosis and management","volume":"14","author":"Alyamany","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.retram.2026.103572_bib0011","doi-asserted-by":"crossref","first-page":"879","DOI":"10.3324\/haematol.2015.140996","article-title":"Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia","volume":"101","author":"Craddock","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.retram.2026.103572_bib0012","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.retram.2026.103572_bib0013","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1158\/1078-0432.CCR-21-3467","article-title":"Impact of venetoclax and azacitidine in treatment-na\u00efve patients with acute myeloid leukemia and IDH1\/2 mutations","volume":"28","author":"Pollyea","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.retram.2026.103572_bib0014","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.retram.2026.103572_bib0015","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1182\/blood-2018-03-828269","article-title":"BCL-2 inhibition in AML: an unexpected bonus?","volume":"132","author":"Konopleva","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.retram.2026.103572_bib0016","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s00277-020-04321-x","article-title":"Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group","volume":"100","author":"Schuler","year":"2021","journal-title":"Ann Hematol"},{"key":"10.1016\/j.retram.2026.103572_bib0017","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.retram.2026.103572_bib0018","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.retram.2026.103572_bib0019","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.27417","article-title":"Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment","author":"Garciaz","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.retram.2026.103572_bib0020","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.19670","article-title":"Fungal infection frequency in newly diagnosed acute myeloid leukaemia patients treated with venetoclax plus azacitidine with or without antifungal prophylaxis","author":"Weinbergerov\u00e1","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.retram.2026.103572_bib0021","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/ejh.14213","article-title":"Fix low dose venetoclax-azacitidine treatment of unfit acute myeloid leukemia patients","volume":"113","author":"Miklos","year":"2024","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.retram.2026.103572_bib0022","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s12032-024-02302-y","article-title":"Venetoclax with decitabine or azacitidine in relapsed or refractory acute myeloid leukemia","volume":"41","author":"Bouligny","year":"2024","journal-title":"Med Oncol"},{"key":"10.1016\/j.retram.2026.103572_bib0023","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1200\/JCO.21.01546","article-title":"Measurable residual disease response and prognosis in treatment-na\u00efve acute myeloid leukemia with venetoclax and azacitidine","volume":"40","author":"Pratz","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.retram.2026.103572_bib0024","doi-asserted-by":"crossref","DOI":"10.1177\/09636897221102902","article-title":"Clinical characteristics and outcome analysis for HLA loss patients following partially mismatched related donor transplantation using HLA chimerism for loss of heterozygosity analysis by next-generation sequencing","volume":"31","author":"Wang","year":"2022","journal-title":"Cell Transpl"},{"key":"10.1016\/j.retram.2026.103572_bib0025","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.retram.2026.103572_bib0026","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41408-023-00928-1","article-title":"Efficacy of venetoclax combined with hypomethylating agents in young, and unfit patients with newly diagnosed core binding factor acute myeloid leukemia","volume":"13","author":"Zhang","year":"2023","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.retram.2026.103572_bib0027","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/bloodadvances.2020003734","article-title":"Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed\/refractory AML","volume":"5","author":"Stahl","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.retram.2026.103572_bib0028","doi-asserted-by":"crossref","first-page":"e404","DOI":"10.3324\/haematol.2018.188094","article-title":"Efficacy of the combination of venetoclax and hypomethylating agents in relapsed\/refractory acute myeloid leukemia","volume":"103","author":"Aldoss","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.retram.2026.103572_bib0029","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41408-024-01054-2","article-title":"RAS mutations in myeloid malignancies: revisiting old questions with novel insights and therapeutic perspectives","volume":"14","author":"Alawieh","year":"2024","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.retram.2026.103572_bib0030","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.3324\/haematol.2022.281214","article-title":"Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-na\u00efve acute myeloid leukemia","volume":"107","author":"Gangat","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.retram.2026.103572_bib0031","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.clml.2024.02.005","article-title":"Hypomethylating agents and venetoclax for acute myeloid leukemia relapsed after hematopoietic stem cell transplant","volume":"24","author":"Ionescu","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.retram.2026.103572_bib0032","doi-asserted-by":"crossref","first-page":"E44","DOI":"10.1002\/ajh.26405","volume":"97","author":"Gao","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.retram.2026.103572_bib0033","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.3324\/haematol.2022.282677","article-title":"Outcome of patients with acute myeloid leukemia following failure of frontline venetoclax plus hypomethylating agent therapy","volume":"108","author":"Gangat","year":"2023","journal-title":"Haematologica"}],"container-title":["Current Research in Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452318626000097?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452318626000097?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T10:56:03Z","timestamp":1777632963000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452318626000097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2452318626000097"],"URL":"https:\/\/doi.org\/10.1016\/j.retram.2026.103572","relation":{},"ISSN":["2452-3186"],"issn-type":[{"value":"2452-3186","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of Venetoclax combined with Azacitidine in the treatment of relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation - a single-center retrospective study","name":"articletitle","label":"Article Title"},{"value":"Current Research in Translational Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.retram.2026.103572","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103572"}}